Just published : A randomized trial of convalescent plasma for moderate covid No benefit. It was underpowered to detect mortality reduction with 464 patients. A large RCT is needed to resolve the question, but these findings are not encouraging.
Phase II study of convalescent plasma for the treatment of #COVID19 in India. >400 adults admitted to hospital with confirmed infection. "Convalescent plasma was not associated with a reduction in progression to severe covid-19 or all cause mortality."
PLACID Trial 🔥PUBLISHED🔥 Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled TRIAL. #COVID19 #idtwitter
Surprisingly (to me at least), this new RCT of 464 patients in India shows that convalescent plasma had no material effectiveness in treatment of patients with moderate or severe COVID19. Via ⁦
Convalescent plasma found to be ineffective in patients admitted to the hospital with moderate #COVID19. Phase II multicentre randomized controlled trial: PLACID study in --> Summary->
Another one bites the dust. A new multicentre trial from India finds that convalescent plasma does not prevent progression to severe covid-19 and does not save lives
Knowing what not to do is as valuable as knowing what to do. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)
Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial) Convalescent plasma was NOT associated with a reduction in progression or all cause mortality.
Moderate sized trial of 464 patients shows convalescent plasma was not associated with a reduction in progression to severe covid-19 or all cause mortality (18% vs 19%)
Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)
Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)
Rough times for the strategy of "passive immunization" against #COVID19. Negative results in hospitalized patients for both convalescent plasma (PLACID RCT, India) & 's LY-CoV555 (aka bamlanivimab) (ACTIV-3 RCT, US)
Pinning your #COVID19 hopes on convalescent plasma? Don't. A new trial finds no benefit. In short, the only helpful treatment is steroids in severe disease but that was likely from past adult respiratory distress trials. #ImportantNegatives